Shots:

• The company initiates a P-III RENOIR trial to evaluate RSVpreF vs PBO in 30-000 adults aged ≥60yrs. with RSV
• The 1EPs of the study is to evaluate the safety & efficacy for the prevention of mod. to sev. LRTI during the first RSV season
• In Nov’18- the vaccine has received FTD from FDA for the prevention of RSV-associated lower respiratory tract illness in infants by active immunization of pregnant women

  | Ref: Pfizer | Image: Wall Street Journal